

# Appendices

## Appendix 1

### Cancer Research UK online researchers' survey June–August 2023

#### Methods note:

- The Hatch team considered 'the Cancer Research UK research community' as those who answered 'Yes' to the question: "Have you received funding from Cancer Research UK or worked on a project receiving funding from Cancer Research UK since 1 January 2021?"
- Cancer Research UK usually uses a wider definition of its community, encompassing those who might have received funding in the past and those who might still reasonably expect to receive Cancer Research UK funding in future, as well as current grantees.
- The survey also collected demographic data not included here to support communications about the survey in order to collect responses from all four UK nations and various demographic groups.

#### Question: How would you describe the type of research you are involved in?

	Total
<b>Total</b>	<b>N = 84*</b>
Prevention, population and public health	13%
Early detection and diagnosis	19%
Discovery	55%
Translational	45%
Clinical trials	37%
Clinical	13%
Data and digital	14%
<b>Count</b>	<b>1.96</b>

#### Question: Are you:

	Total
<b>Total</b>	<b>N = 79*</b>
UK national	58%
EU or EEA national	28%
Other national	3%
Dual UK-EU/EEA national	9%
Dual UK-Other national	4%
Dual EU/EEA-Other national	0%
<b>Count</b>	<b>1.01</b>

Question: Please select the type(s) of organisation(s) where you hold your main role(s)

	Total
<b>Total</b>	<b>N = 79*</b>
University	73%
Cancer Research UK core-funded institute	10%
Cancer Research UK centre	24%
Clinical trial unit	5%
Experimental Cancer Medicine Centre (ECMC)	1%
Health service	13%
Other	10%
<b>Count</b>	<b>1.37</b>

Question: Throughout this survey, we ask for your experiences since 1 January 2021 – the UK-EU trade agreement (the "Brexit deal") applied from that date.

**Have you received funding from Cancer Research UK or worked on a project receiving funding from Cancer Research UK since 1 January 2021?** (Projects that began before 1 January 2021 are ONLY included if they continued after 1 January 2021).

	Total
<b>Total</b>	<b>N=84*</b>
Yes	77%
No	18%
Other	4%
Don't know	1%

Question: (For those based in the UK). Are you currently involved in any kind of multinational collaboration? ie collaborators are based outside the UK.

	Total
<b>Total</b>	<b>N=79*</b>
Yes	78%
No	19%
Don't know	3%

Question: What kind of multinational collaborations/activities are you involved with?

	Total
<b>Total</b>	<b>N = 62*</b>
A project with individuals/teams based in EU and/or other European countries	89%
A project with individuals/teams based in the rest of the world	69%
A project with an international organisation (eg European Commission, International Agency for Research on Cancer/World Health Organisation)	15%
Peer review	50%
A pan-European professional association/group	21%
A global professional association/group	19%
Other	2%
<b>Count</b>	<b>2.65</b>

Question (for the 6% who responded from within the EU): How do you interact with UK-based scientists and others involved in research?

	Total
<b>Total</b>	<b>N = 5**</b>
A project with individuals/teams based in the UK	100%
A project with individuals/teams based in the UK and EU/EEA countries	60%
A project with individuals/teams based in the UK and rest of the world	20%
A project with an international organisation (eg European Commission, International Agency for Research on Cancer/World Health Organisation)	0%
Peer review	20%
A pan-European association/group	0%
A global association/group	0%
Other	0%

Question: Which countries around the world are most likely to be involved in your future collaborations?

Row labels	Count of mentions EU	% of respondents
	7	8.3
Yes	77	91.7
<b>Total</b>	<b>84</b>	

Name	Count of country listed	% of respondents
United States	49	58.3
United Kingdom	31	36.9
Germany	29	34.5
France	25	29.8
The Netherlands	20	23.8
Spain	19	22.6
Italy	16	19.0
Canada	11	13.1
Switzerland	11	13.1
Sweden	8	9.5
Australia	8	9.5
Norway	7	8.3
Denmark	6	7.1
Ireland	6	7.1
Belgium	5	6.0
Austria	4	4.8
Japan	2	2.4
Greece	2	2.4
Russia	1	1.2
China	1	1.2
Finland	1	1.2
Croatia	1	1.2
Estonia	1	1.2
South Korea	1	1.2
Singapore	1	1.2
Lithuania	1	1.2
Israel	1	1.2
Uganda	1	1.2
Czech Republic	1	1.2
Iran	1	1.2
Iceland	1	1.2
India	1	1.2
Nigeria	1	1.2
<b>Total</b>	<b>274</b>	

Question: We'd like to understand more about the interactions you have beyond the UK for your work. This relates to the whole spectrum from formal scientific collaborations to informal knowledge exchange. Thinking about your collaborations, partnerships and other professional cooperation beyond the UK: how important to you is collaboration with EU-based scientists and others involved in research?

	Total
<b>Total</b>	<b>N = 79*</b>
Not at all important	0%
Not very important	3%
Fairly important	14%
Very important	84%
Don't know	0%

Question (for the 6% who responded from the EU): How important to you is collaboration with UK-based scientists and others involved in research?

	Total
<b>Total</b>	<b>N = 5**</b>
Not at all important	0%
Not very important	20%
Fairly important	20%
Very important	60%
Don't know	0%

Question: Do you agree or disagree with the following statement? "Since 1 January 2021, it has been harder to begin new collaborations with scientists and others involved in research based in EU countries."

	Total
<b>Total</b>	<b>N = 79*</b>
Strongly disagree	6%
Disagree	6%
Neither agree nor disagree	8%
Agree	35%
Strongly agree	44%

Question (for the 6% who responded from EU countries): Do you agree or disagree with the following statement? "Since 1 January 2021, it has been harder to begin new collaborations with scientists and others involved in research based in the UK."

	Total
<b>Total</b>	<b>N = 5**</b>
Strongly disagree	0%
Disagree	0%
Neither agree nor disagree	40%
Agree	20%
Strongly agree	40%

Question: Which three factors are most important to succeed in your research?

	Total
<b>Total</b>	<b>N = 79*</b>
Recruitment and retention of talent	76%
Ease of collaboration with partners based in EU countries	54%
Ease of collaboration with partners based in the rest of the world	19%
Ability to share personal health data across borders (with appropriate safeguards)	20%
Stable supply of items for your research setting, including the medicinal products/devices used in research	43%
Access to EU funding	46%
Ability to play an active role in networks/professional associations beyond the UK	38%
Other	4%

Question: Do you agree or disagree with the following statement? "Since 1 January 2021 (when the "Brexit deal" came into force), it has become harder to carry out research."

	Total
<b>Total</b>	<b>N = 84*</b>
Strongly disagree	5%
Disagree	2%
Neither agree nor disagree	11%
Agree	39%
Strongly agree	43%

Question: How important is it that the UK and EU continue to allow scientists to share personal health data across borders (with appropriate safeguards)?

	Total
<b>Total</b>	<b>N = 84*</b>
Not at all important	0%
Not very important	5%
Fairly important	15%
Very important	74%
Don't know	6%

Question: Have you faced any difficulties in recruitment and retention of staff due to the new UK-EU relationship, and/or with your own plans?

	Total
<b>Total</b>	<b>N = 79*</b>
No	16%
Yes	76%
Don't know	8%

Question: How important is funding from the EU (for example, from the European Research Council) relative to other sources of funding for your research?

	Total
<b>Total</b>	<b>N = 79*</b>
Not at all important	6%
Not very important	15%
Fairly important	27%
Extremely important	44%
Don't know	8%

Question: Which of these options best represents your preferred outcome on the UK's participation in Horizon Europe?

	Total
<b>Total</b>	<b>N = 84*</b>
Associate membership of Horizon Europe and future European funding programmes, with direct access to EU funding	75%
A new UK-based scheme which provides funding from the UK Government as a replacement for direct EU funds	11%
Don't know	14%

## Appendix 2

### Cancer Research UK Patient Involvement Network online survey 2023

Question: To what extent do you agree or disagree with the following statement?  
“Cancer Research UK’s researchers must be able to start and continue new projects easily with partners around the world, including those based in EU countries.”

	Total
<b>Total</b>	<b>N = 78*</b>
Strongly agree	96%
Agree	3%
Neither agree or disagree	0%
Disagree	0%
Strongly disagree	1%

Question: To what extent do you agree or disagree with the following statement? “The UK and EU must take action to reduce paperwork, costs and delays so that clinical trials can operate easily across borders.”

	Total
<b>Total</b>	<b>N = 78*</b>
Strongly agree	91%
Agree	6%
Neither agree or disagree	1%
Disagree	0%
Strongly disagree	1%

Question: To what extent do you agree with the following statement? “It is vital the UK remains an attractive place for cancer researchers and their families to come to work.”

	Total
<b>Total</b>	<b>N = 78*</b>
Strongly agree	85%
Agree	10%
Neither agree or disagree	5%
Disagree	0%
Strongly disagree	0%



Question: To what extent do you agree with the following statement? "In future, Cancer Research UK scientists and their research partners in other countries must be able to share personal health data – with appropriate safeguards for privacy and confidentiality – at least as easily as they do now."

	Total
<b>Total</b>	<b>N = 78*</b>
Strongly agree	88%
Agree	8%
Neither agree or disagree	4%
Disagree	0%
Strongly disagree	0%

Question: To what extent do you agree or disagree with the following statement? "The UK must continue to participate in, and fund our proportion of, major EU research programmes that support scientific collaboration around the world."

	Total
<b>Total</b>	<b>N = 78*</b>
Strongly agree	92%
Agree	3%
Neither agree or disagree	4%
Disagree	0%
Strongly disagree	1%

Question: To what extent do you agree or disagree with the following statement? "The UK and EU should take action to make it easier for scientists in different countries to collaborate to understand children's and young people's cancers and to develop new treatments."

	Total
<b>Total</b>	<b>N = 78*</b>
Strongly agree	91%
Agree	6%
Neither agree or disagree	1%
Disagree	0%
Strongly disagree	1%

Question: Below is a list of the key changes our scientists would like to see, to help improve research collaboration. We'd like to understand which of these changes are most important to you.

	Total
Total	N = 78*
Reduce any delays or extra costs that could prevent new treatment options getting to patients as quickly as possible	38%
Make it easier for top cancer researchers around the world to come to the UK for work	8%
Make sure UK laws work well enough with the laws of other countries and with EU laws to make research collaboration as easy as possible	23%
Make sure cancer researchers can share data with each other to make faster progress, as long as they take the right steps to keep people’s personal information private	31%